Kymera Therapeutics Inc. (KYMR)
NASDAQ
110.76
-0.09 (-0.08%)
Closed
Oct 23, 2026
Day's Range
109.05111.83
52 wk Range
55.26130.05
Financial Statements - KYMR - Kymera Therapeutics Inc.
Revenue
39.21M▼ 16.7%
Net Income
-311.35M▼ 39.1%Net Margin -794.0%
EBITDA
-298.81M▼ 41.4%
Free Cash Flow
-234.34M▼ 13.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 39.21M | 47.07M | 78.59M | 46.82M | 72.83M | 34.03M |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -345.54M | -256.71M | -165.53M | -161.25M | -100.53M | -46.30M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -3.85M | -4.92M | - | - | - | - |
| Pre Tax Income | -311.35M | -223.85M | -146.96M | -154.80M | -100.21M | -45.59M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -311.35M | -223.85M | -146.96M | -154.80M | -100.21M | -45.59M |
| EPS Basic | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 | -3.15 |
| EPS Diluted | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 | -3.15 |
| Basic Shares Outstanding | 84.49M | 75.04M | 58.36M | 53.93M | 47.98M | 17.34M |
| Diluted Shares Outstanding | 84.49M | 75.04M | 58.36M | 53.93M | 47.98M | 17.34M |
| Ebit | -310.98M | -223.60M | -146.76M | -154.63M | -100.04M | -45.47M |
| Ebitda | -298.81M | -211.31M | -143.20M | -151.65M | -97.64M | -43.71M |
| Net Income Continuous Operations | -311.35M | -223.85M | -146.96M | -154.80M | -100.21M | -45.59M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
